Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases
Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and ...
Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization
Company also reports preliminary unaudited 2024 revenue of $701.0 millionPARSIPPANY, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver ...